In brief: Benitec, XRT, Phylogica, Norwood Abbey
Wednesday, 06 April, 2005
RNAi specialist Benitec (ASX:BLT) has lodged a prospectus with ASIC to raise up to AUD$9.7 million in a rights issue, underwritten by Bell Potter. Capital raised will go towards clinical development and expansion of Benitec's California operations, it said.
Unlisted imaging company XRT, an investee of BioTech Capital (ASX:BTC), has entered a deal in which an unnamed analytical company will incorporate XRT's phase contrast technology in 3D metrology and analysis instruments.
Drug discovery firm Phylogica (ASX:PYC) has named former Peptech and CSL executive Dr Greg Pullen as its chief operating officer. Most recently, Pullen was in charge of licensing at Auckland University's commercialisation entity.
Norwood Abbey (ASX:NAL) has won TGA approval for a key component of its vision correction surgery tool Epi-Lasik.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
